Evaluating Downstream Processing Options at the Bioprocess-business interface

评估生物工艺-业务界面的下游处理选项

• 批准号: 100432
• 金额: $ 7.56万
• 依托单位: MEDIMMUNE LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2007
• 资助国家: 英国
• 起止时间: 2007 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=100432
• 关键词: Evaluating; Downstream; Processing; Options; Bioprocess

The cost to patients and healthcare providers for Monoclonal Antibody (MAb) treaments has traditionally been high. The complex process required to generate, purify and formulate the drug add significantly to the overall cost. Although efforts have been made to reduce costs by looking at increasing manufacturing efficiencies e.g., selection of new chromatography sequences and strategies, this effort has been impeded by a lack of a systematic framework to assess the process-business trade-offs of competing process configurations. The goal of this project was to generate computer-based decision-support algorithms that assess the operational and business outcomes of future bioprocessing strategies for MAbs. By combining detailed process economic models, multi-objective decision analysis and combinatorial optimisation techniques with suitable methods of visualising the process-business interactions to create a powerful holistic tool for prioritising cost-effective downstream manufacturing.

传统上，患者和医疗保健提供者使用单抗治疗的成本很高。生产、提纯和配制该药物所需的复杂过程大大增加了总成本。虽然已经努力通过提高制造效率来降低成本，例如，选择新的层析序列和策略，但由于缺乏评估竞争工艺配置的工艺-业务权衡的系统框架，这一努力一直受到阻碍。该项目的目标是生成以计算机为基础的决策支持算法，以评估单抗未来生物处理战略的操作和业务成果。通过将详细的流程经济模型、多目标决策分析和组合优化技术与可视化流程-业务交互的适当方法相结合，创建了一个强大的整体工具，用于优先考虑具有成本效益的下游制造。